Sentinext raises $14m Series B funding 

Sentinext raises $14m Series B funding 

Sentinext Therapeutics has successfully completed $14 million Series B financing to further develop its vaccine against the hand, foot & mouth disease (HMFD).

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter